Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q2VIR3
UPID:
IF2GL_HUMAN
Alternative names:
Eukaryotic translation initiation factor 2 subunit gamma A
Alternative UPACC:
Q2VIR3; F8W810; Q5I0X0; Q6KF84
Background:
Eukaryotic translation initiation factor 2 subunit 3B (EIF2S3B) plays a pivotal role in protein synthesis. As a member of the eIF2 complex, it is instrumental in the early steps of translation, forming a ternary complex essential for the initiation process. This complex's interaction with ribosomal subunits facilitates the formation of the 43S pre-initiation and 80S initiation complexes, crucial for mRNA binding and protein synthesis.
Therapeutic significance:
Understanding the role of Eukaryotic translation initiation factor 2 subunit 3B could open doors to potential therapeutic strategies. Its central function in protein synthesis makes it a potential target for interventions in diseases where protein synthesis plays a role.